TORONTO, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Wayland Group (CSE:WAYL) (FRANKFURT: 75M) ( OTCQB:MRRCF) (“Wayland”
or the “Company) is pleased to announce receipt of accreditation for its proprietary education program for pharmacists from the
Canadian Council on Continuing Education in Pharmacy (the CCCEP).
The Company has identified that pharmacists are the most accessible and one of the most trusted health
professionals in the Canadian healthcare system which makes them a critical component in the provision of patient care. In
cooperation with the Company’s joint venture pharmacy partners, Wayland developed cannabis education programs, including this
comprehensive online education platform to raise the standard of care across Canada. These programs will be available to
pharmacists in over 2,100 pharmacies, coast to coast.
Wayland believes that there is a national need for education and more importantly practical guidance for medical
cannabis therapy, assessment, dosing and monitoring to ensure safe and appropriate use for patients. As many cannabis patients
present with comorbidities and take multiple medications, which require appropriate management to help avoid adverse side
effects.
The Wayland program incorporates online learning tools including, webinars, educational events and educational
resources specifically for pharmacists and clinicians. The Educational Program, which launched on October 1, 2018 - is accredited
by the CCCEP for pharmacists on the clinical and practical application of cannabinoid therapy. In addition, it includes practice
guides, instructional videos, dosing protocols and patient support materials which can be used by physicians and the full circle of
care.
“We’re proud to elevate the standard of care provided to patients through an expert led educational platform
that provides pharmacists and physicians the ability to become experts in cannabis and share this with their patients to enhance
their quality of life,” said Ben Ward, CEO. “We’re taking this platform now to other countries to help medical professionals
understand cannabis, so they can speak in plain language to their patients regarding potential benefits.”
Maricann Group Inc., through its subsidiaries, is operating under the Wayland Group name. For further details
see the press release dated September 24, 2018.
About Wayland Group Corp.
Wayland is a vertically integrated producer and distributor of cannabis for medical purposes. The Company was
founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario
where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from
the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland.
Wayland is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq.
m) footprint upon full buildout and will continue to pursue new opportunities in Europe.
Forward Looking Statements
This news release includes forward-looking information and statements, which may include, but are not limited
to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other
plans, intentions, expectations, estimates, and beliefs of the Company. Forward-looking information and statements involve and are
subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results,
performance, or achievements of the Company to be materially different from future events, results, performance, and achievements
expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking
information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties
inherent in such information and statements, there can be no assurance that any such forward-looking information and statements
will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and
should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and
statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and
disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that
actual events or results could or do differ from those projected in any forward looking information and statements herein, whether
as a result of new information, future events or results, or otherwise, except as required by applicable laws.
The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news
release.
For more information about Wayland, please visit our website at www.waylandgroup.com
CONTACT INFORMATION
Investor Relations
Graham Farrell
VP, Communications
Graham.Farrell@waylandgroup.com
647-643-7665
For media inquiries please contact media@waylandgroup.com
Corporate Headquarters (Canada)
Wayland Group Corp. (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
Canada
289-288-6274
European Headquarters (Germany)
Maricann GmbH
Thierschstrasse 3, 80538 Munchen, Deutschland
